The short version of wound model fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-17 and is reviewed periodically as new material appears.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
==== Attachment and biofilm formation ==== Attachment is another important method for regulating algicidal activity, as it can elongate the duration of interactions between bacteria and algae. It was observed that the number of attached bacteria per diatom was positively correlated with the lysis rate of algal cells, and the lysis rate increased when attachment rates were elevated. Attachment can be strengthened through biofilm formation, which consists of extracellular polymeric substances (EPS), adhesins, and other components capable of aggregating cells together. Biofilms allow for elongated interactions between bacteria and algal cells, and maintain the exchange of nutrients and gases.
== J == Nancy B. Jackson (1956–2022), American chemist who worked on heterogeneous catalysis and the development of alternative fuels Marilyn E. Jacox (1929–2013), American chemist who worked on the spectroscopy of free radicals and other unstable chemical species Hope Jahren (born 1969), American chemist and isotope analyst known for using stable isotope analysis to analyze fossil forests Paul Janssen (1926–2003), Belgian physician and entrepreneur who discovered the antispasmodic drug ambucetamide Allene Jeanes (1906–1995), American chemist who developed Dextran to replace plasma in the Korean War Frédéric Joliot-Curie (1900–1958), French chemist and physicist, 1935 Nobel Prize in Chemistry for the discovery of induced radioactivity Irène Joliot-Curie (1897–1956), French chemist and physicist, 1935 Nobel Prize in Chemistry for the discovery of induced radioactivity Madeleine M. Joullié (born 1927), French-American-Brazilian organic chemist who worked on synthesizing organic compounds such as tilorone, furanomycin, and numerous cyclopeptides Percy Lavon Julian (1899–1975), African American organic chemist who was a pioneer in the chemical synthesis of medicinal drugs from plants. He was the first to synthesize the natural product physostigmine.
Diagnose and treat oral disease (preventive and restorative) Interpret x-rays and other diagnostic tests Formulate treatment plans to restore oral health of pediatric patients including healthy one and those with special health care needs Monitor growth and development of all teeth and jaws Treat dental malocclusion interceptive orthodontic treatment and/or orthodontics Perform surgical procedures on teeth, bone, and soft tissues of the oral cavity Provide emergency care(dental infection, pain, and dental trauma) Treat pediatric patients under different levels of sedation (minimal, moderate, or deep) and general anesthesia
== History and research == Research in the early 1960s showed that in rats, administration of α-MSH caused sexual arousal, and work on this continued in many labs up through the 1980s, when scientists at the University of Arizona began attempting to develop α-MSH and analogs as potential sunless tanning agents, and synthesized and tested several analogs, including melanotan-I and melanotan II. Early in the research process one of the scientists, who was conducting experiments on himself with an early tool compound, melanotan II, injected himself with twice the dose he intended to and got an eight-hour erection, along with nausea and vomiting. As a tanning agent, melanotan I (now known as afamelanotide) was licensed by Competitive Technologies, a technology transfer company operating on behalf of the University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. Afamelanotide was approved by the FDA in 2019. As a sexual dysfunction agent, melanotan II was licensed by Competitive Technologies to Palatin Technologies. Palatin ceased development of melanotan II in 2000 and synthesized, patented, and began to develop bremelanotide, a likely metabolite of melanotan II that differs in that it has a carboxy group where melanotan II has an amide. Competitive Technologies (Clinuvel) sued Palatin for breach of contract and tried to claim ownership of bremelanotide; the parties settled in 2008 with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying US$800,000.
in situ hybridization (ISH) A hybridization probe assay in which a labeled, single-stranded DNA or RNA molecule or nucleic acid analogue containing a sequence that is complementary to a particular DNA or RNA sequence is allowed to hybridize with its complement in situ, i.e. in its natural context, such as within cells or tissue sections (as opposed to within homogeneous samples extracted from cells or tissues, where cellular or histological structure has been lost in the process of obtaining the sample), in order to reveal the precise location of the complementary sequence within this context. The label may be a radioactive compound, fluorescent molecule, or hapten, permitting detection by a variety of visualization techniques. In situ hybridization is commonly used to identify the physical locations of specific DNA sequences such as genes and regulatory elements on chromosomes, which can provide insight into chromosomal structure and integrity; to determine the subcellular locations where various types of RNA accumulate and interact with other molecules; and to visualize the tissues and organs within an organism where specific genes are expressed at various developmental stages (by probing for the genes' RNA transcripts).
Sources: en.wikipedia.org
== Regulatory harmonization == In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and the European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
=== United Kingdom === The following scope of practice has been outlined by the General Dental council for registered clinical dental technologist. Clinical dental technologist in the United Kingdom can:
=== Netherlands === In the Netherlands, all parts of Papaver somniferum after harvesting (except for the seeds) are illegal by law, as they are Listed as drugs in the Opium Law. Because of use for decorative purposes, the trade in, and possession of dried Papaver somniferum is not actively prosecuted. Trade in, or possession of dried Papaver somniferum with the intention of drug use can be prosecuted. The dried seed pod of Papaver somniferum is easily obtainable as it is commonly available for decorative use. Many varieties, strains, and cultivars of Papaver somniferum are in existence, and the alkaloid content can vary significantly.
Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are extracted from the patient, genetically engineered to recognize tumor-specific antigens, and returned to the patient. Cell types that can be used in this way are natural killer (NK) cells, lymphokine-activated killer cells, cytotoxic T cells, and dendritic cells. Finally, specific antibodies can be developed that recognize cancer cells and target them for destruction by the immune system. Examples of such antibodies include rituximab (targeting CD-20), trastuzumab (targeting HER-2), and cetuximab (targeting EGFR). Passive antibody therapies aim to increase the activity of the immune system without specifically targeting cancer cells. For example, cytokines directly stimulate the immune system and increase immune activity. Checkpoint inhibitors target proteins (immune checkpoints) that normally dampen the immune response. This enhances the ability of the immune system to attack cancer cells. Current research is identifying new potential targets to enhance immune function. Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab.
A compartment kiln is filled with a static batch of timber through which air is circulated. In these types of kiln, the timber remains stationary. The drying conditions are successively varied according to the type of timber being dried. This drying method is well suited to the needs of timber companies, which have to dry timbers of varied species and thickness, including refractory hardwoods that are more liable than other species to check and split. The main elements of chamber drying are:
Sources: en.wikipedia.org
Applications of this method include the analysis of fragile molecules and guest-host interactions that cannot be studied using regular electrospray ionization. Electrospray ionization has also been achieved at pressures as low as 25 torr and termed subambient pressure ionization with nanoelectrospray (SPIN) based upon a two-stage ion funnel interface developed by Richard D. Smith and coworkers. The SPIN implementation provided increased sensitivity due to the use of ion funnels that helped confine and transfer ions to the lower pressure region of the mass spectrometer. Nanoelectrospray emitter is made out of a fine capillary with a small aperture about 1–3 micrometer. For sufficient conductivity this capillary is usually sputter-coated with conductive material, e.g. gold. Nanoelectrospray ionization consumes only a few microliters of a sample and forms smaller droplets. Operation at low pressure was particularly effective for low flow rates where the smaller electrospray droplet size allowed effective desolvation and ion formation to be achieved. As a result, the researchers were later able to demonstrate achieving an excess of 50% overall ionization utilization efficiency for transfer of ions from the liquid phase, into the gas phase as ions, and through the dual ion funnel interface to the mass spectrometer.
Thiel and Angermayer agreed to invest after a lunch, also held for members of the gay tech community, around mid-2023. The Wired notes that Thiel and Angermayer were not particularly interested in sports, but D'Souza was a savvy fundraiser. Angermayer said his backing of TEG stems from his belief that AI will create more leisure time and boost demand for sports entertainment. He said, "Humans are wired to want to see the fastest man or woman [...] They don't want to see the fastest natural man."
In 2004, Lilly-ICOS, Pfizer, and GlaxoSmithKline spent a combined $373.1 million to advertise Cialis, Viagra, and Levitra respectively. Cialis has sponsored many sporting events, including the America's Cup and the PGA Tour, once being title sponsor of the PGA Tour Western Open tournament.
== History == Two of the drug's three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and a third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, then branch chief of the NML, and is undergoing further development by Leaf Biopharmaceutical (LeafBio, Inc.), a San Diego–based arm of Mapp Biopharmaceutical. LeafBio created ZMapp in collaboration with its parent and Defyrus Inc., each of which had licensed its own cocktail of antibodies, called MB-003 and ZMab.
Black Detroiters tended to have far less access to New Deal mortgage support programs such as Federal Housing Authority and Veterans Administration insured mortgages. African-American neighborhoods were viewed by lenders and the federal programs as riskier, resulting—in this period—in much lower rates of homeownership for African-Americans than other residents of the city. The auto industry also gave rise to a large number of high paying management and executive jobs. There were also large numbers of attorneys, advertisers, and other workers who supported the industry's managerial force. These workers already by the 1920s had begun to move to neighborhoods well removed from the industry's factories and higher crime rates. This upper stratum moved to outlying neighborhoods, and further, to well-to-do suburbs such as Bloomfield Hills and Grosse Pointe. Oakland County, north of the city, became a popular place to live for executives in the industry. "By the second half of the twentieth century, it was one of the wealthiest counties in the United States, a place profoundly shaped by the concentration of auto-industry-derived wealth." Public policy was automobile oriented. Funds were directed to the building of expressways for automobile traffic, to the detriment of public transit and the inner-city neighborhoods through which the expressways were cut to get to the auto factories and the downtown office buildings.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.